Ginkgo Bioworks (NYSE: DNA), a Boston, MA-based company which is building a platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, a life sciences tools, diagnostics and computational discovery company.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).

Myriad Genetics said Thursday that it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics' laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.

US-based Calibre Scientific has acquired German MoBiTech for an undisclosed amount to bolster its portfolio of diagnostic services.

US-based Veracyte has agreed to acquire minimal residual disease (MRD) test developer C2i genomics in a deal worth up to $95m, strengthening its range of cancer diagnostic products.

GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.

Swiss drugmaker Roche (ROG.S) said on Friday it has agreed to buy LumiraDx's (LMDX.O) Point of Care diagnostics platform business for about $295 million.

Bruker has entered into an agreement with private equity firm PAI Partners to purchase EliTechGroup, PAI announced on Wednesday.